<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303715</url>
  </required_header>
  <id_info>
    <org_study_id>NAUTILUS study</org_study_id>
    <nct_id>NCT04303715</nct_id>
  </id_info>
  <brief_title>No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography</brief_title>
  <official_title>No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography[NAUTILUS]: A Prospective, Multicenter, Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Evidence-Based Healthcare Collaborating Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NAUTILUS study is a prospective, multicenter, RCT. Clinically T1,T2, node negative BCS&#xD;
      candidates with no evidence of metastases in AUS are 1:1 randomized into no SLNB group and&#xD;
      SLNB group.&#xD;
&#xD;
      NAUTILUS study aim to establish the minimally invasive treatment of breast cancer by&#xD;
      reexamining the necessity of sentinel lymph node biopsy among patients with invasive breast&#xD;
      cancer who have tumors under 5cm, are clinically node-negative, and are having breast&#xD;
      conserving surgery performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Background] Skipping ALND, the follow-up treatment in SN-positive patients, has non-inferior&#xD;
      oncological outcomes compared to SLNB-only group, given that there is no severe SN&#xD;
      metastases.&#xD;
&#xD;
      Axillary ultrasound can effectively exclude high nodal burden, showing 95% NPV in a&#xD;
      systematic review.&#xD;
&#xD;
      SLNB has morbidity including lymphedema, limited range of motion, pain, and other&#xD;
      post-surgical complications, eventually leading to reduced quality of life.&#xD;
&#xD;
      Considering improvement of imaging modalities and adjuvant care, survival outcome of SLNB&#xD;
      must be re-evaluated. Especially research reflective of the regional specificities of Korea&#xD;
      and Asia-Pacific is needed.&#xD;
&#xD;
      [Study design] Prospective, Multicenter, RCT.&#xD;
&#xD;
      [Statistical considerations] According to Z0011 trial, 5yr DFS in eligible patients is&#xD;
      expected to be 86%, which is between previous data of 88.6% in cT1,2 and SN-negative&#xD;
      patients4, and 83.9% in cT1,2 and 1-2 SN-positive patients.&#xD;
&#xD;
      Non-inferiority margin is set at 5%. With 5% significance level and 80% power, 780 patients&#xD;
      are needed in each group. Assuming a 10% drop out rate, 1734 patients need to be recruited.&#xD;
&#xD;
      [Screening and Randomization] Participants undergo screening tests that assess eligibility&#xD;
      according to inclusion/exclusion criteria.&#xD;
&#xD;
      In order to identify axillary lymph node metastases, axillary ultrasound is first performed&#xD;
      by radiologists. Patients showing normal features are enrolled, while for conditionally&#xD;
      normal patients, with only 1 suspicion of low nodal burden, axillary lymph node biopsy should&#xD;
      be performed. Suspicious patients are excluded under following conditions: patients with 1 or&#xD;
      more suspicion of high nodal burden, 2 or more suspicion of low nodal burden, or T2 invasive&#xD;
      lobular carcinoma patients with 1 or more low nodal burden. The severity of nodal burden is&#xD;
      defined through the criteria.&#xD;
&#xD;
      Patients who underwent radiological axillary staging are randomly assigned (1:1) to the study&#xD;
      arm and the control arm before surgical care. Stratification is done based on trial centers&#xD;
      and tumor sizes.&#xD;
&#xD;
      [Post-surgical care] All patients are planned to receive ipsilateral whole breast radiation.&#xD;
      Patients randomized to non-SLNB arm are recommended to follow high tangential radiotherapy&#xD;
      protocol, in which upper margin of radiation field includes axillary level I and II or lies&#xD;
      within 2CM from humeral head.&#xD;
&#xD;
      Additional treatment may be performed if deemed necessary by the researcher&#xD;
&#xD;
      [Objectives]&#xD;
&#xD;
        1. Primary objective&#xD;
&#xD;
           - 5yr invasive Disease Free Survival&#xD;
&#xD;
        2. Secondary objectives&#xD;
&#xD;
             -  5yr Overall Survival&#xD;
&#xD;
             -  5yr Distant Metastasis Free Survival&#xD;
&#xD;
             -  Axillary recurrence rate&#xD;
&#xD;
             -  Patient reported AE&#xD;
&#xD;
             -  QoL&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>invasive Disease Free Survival (iDFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate invasive disease free survivals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis Free Survival (DMFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate distant metastasis free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axillary recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate ipsilateral axillary recurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Recurrence Rate (LRR)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate locoregional recurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Adverse Events (AEs)</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate Patient reported Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate Quality of Life of patient by EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1734</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Sentinel Lymph Node</condition>
  <arm_group>
    <arm_group_label>No SLNB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study arm - BCS without SLNB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLNB group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Control Arm - BCS with SLNB(+/-ALND)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No SLNB</intervention_name>
    <description>BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients</description>
    <arm_group_label>No SLNB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SLNB</intervention_name>
    <description>BCS with SLNB(+/-ALND)</description>
    <arm_group_label>SLNB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ≥ 19 years&#xD;
&#xD;
          -  Invasive unilateral breast carcinoma with histological confirmation&#xD;
&#xD;
          -  History of invasive breast cancer&#xD;
&#xD;
          -  Histologically or radiologically no suspicion of distant metastases&#xD;
&#xD;
          -  Performance status corresponding to ECOG grade 0-2&#xD;
&#xD;
          -  Tumor size clinically and radiologically ≤ 5cm, independent of hormone receptor and&#xD;
             HER2 status&#xD;
&#xD;
          -  Clinically and sonographically negative axillary lymph nodes before biopsy; core&#xD;
             needle biopsy or fine needle aspiration of suspicious lymph node required&#xD;
&#xD;
          -  BCS candidate with postoperative whole-breast irradiation and adequate systemic&#xD;
             therapy&#xD;
&#xD;
          -  No psychological and geographical restriction in follow-up&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any cancer in the previous 5 years&#xD;
&#xD;
          -  Bilateral breast cancer&#xD;
&#xD;
          -  Invasive breast cancer treated with neoadjuvant therapy&#xD;
&#xD;
          -  Tumor size clinically and radiologically &gt; 5cm&#xD;
&#xD;
          -  Mastectomy candidate&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Male breast cancer&#xD;
&#xD;
          -  Unable to understand and fill out questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonshik Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wonshik Han</last_name>
    <phone>+82-2-2072-1958</phone>
    <email>hanw@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Gwang Jung</last_name>
    <phone>+82-2-2072-1958</phone>
    <email>mc2plato@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wonshik Han, MD</last_name>
      <phone>02-2072-1958</phone>
      <email>hanw@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji Gwang Jung, MD</last_name>
      <phone>02-2072-1958</phone>
      <email>mc2plato@snu.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Wonshik Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Gwang Jung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

